ResearcherKantonsspital WinterthurActive in the last 2 years
Lukasz F. Grochola
Matched on ORCID iD 0000-0002-7606-7266; OpenAlex author ID A5004992476.
Their work
- Papers
- 4 (first author 1, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 6
2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper
Papers 4
- A Predictive Noninvasive Single-Nucleotide Variation-Based Biomarker Signature for Resectable Pancreatic Cancer: Protocol for a Prospective Validation Study. Last author DOI 10.2196/54042↗
- Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants. Last author DOI 10.1001/jamasurg.2019.0484↗
- CD44 SNPrs187115: A Novel Biomarker Signature that Predicts Survival in Resectable Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-16-0058↗
- Elevated transcript levels from the MDM2 P1 promoter and low p53 transcript levels are associated with poor prognosis in human pancreatic ductal adenocarcinoma. First author DOI 10.1097/mpa.0b013e3181f95104↗
Closest collaborators
The 6 strongest of 6 ranked by shared papers, trials and grants, with recent and small-team work weighing most.
- Nico Seeger · 1 shared paper, 2024
- Peter Würl · 2 shared papers, 2011–2016
- Paper CD44 SNPrs187115: A Novel Biomarker Signature that Predicts Survival in Resectable Pancreatic Ductal Adenocarcinoma. DOI 10.1158/1078-0432.ccr-16-0058↗
- Paper Elevated transcript levels from the MDM2 P1 promoter and low p53 transcript levels are associated with poor prognosis i… DOI 10.1097/mpa.0b013e3181f95104↗
- Christos M. Dimitrakopoulos · 1 shared paper, 2019
- Giovanni Stracquadanio · 1 shared paper, 2016
- Pierre-Alain Clavien · 1 shared paper, 2016
- Andrej Udelnow · 1 shared paper, 2011
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.